A prospective cohort study on whether proton pump inhibitors aggravate cisplatin-induced acute renal injury

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039569

Enrollment

Unknown

Registered

2020-10-31

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute renal injury

Interventions

PPIs group:PPIs and Cisplatin

Non PPIs group:Cisplatin

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (with the following 4 criteria). (1) The age of the patient ranged from 18 to 75 years old (18 years old, 75 years old), and the expected survival time was more than 3 months. (2) Patients with nasopharyngeal carcinoma, lung cancer, ovarian cancer, cervical cancer, esophageal cancer and gastric cancer diagnosed by pathology. (3) Karnofsky score 60. (4) The patients were treated with cisplatin chemotherapy. (5) Routine determination of serum creatinine during hospitalization.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (with any of the following criteria). (1) Chronic kidney disease (CKD). (2) Patients with end-stage renal disease (renal transplant patients, patients with eGFR < 30 ml/min per 1.73m2 or receiving maintenance renal dialysis). (3) Patients with multiple organ failure. (4) Patients with AKI occurred before chemotherapy. (5) Patients who use methotrexate, mycotoxin, mitomycin C, nitrosourea and other nephrotoxic chemotherapeutic drugs at the same time. (6) Within 2 weeks before the unconventional use of PPIs chemotherapy, the patient needed to use PPIs dose for intravenous drip of 40mg/d with omeprazole sodium. (7) The primary malignant tumor invaded or metastasized to the kidney, ureter, bladder and other organs. (8) Patients with mental disorders. (9) The researchers do not think it is appropriate to take part in this experiment. (10) According to the judgment of the researchers, there are serious hazards to the safety of patients or concomitant diseases that affect the completion of the study. (11) People who are known to be allergic to the therapeutic drugs used in the trial.

Design outcomes

Primary

Measure	Time frame
Serum creatinine;	—

Countries

China

Contacts

Public ContactLuo Hai-Qing

Affiliated Hospital of Guangdong Medical University

hqluo@126.com+86 13729196345

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026